The impact of P-glycoprotein mediated efflux on absorption of 11 sedating and less-sedating antihistamines using Caco-2 monolayers

References

• Artursson P, Palm K, Luthman K. (1996). Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Del Rev 22:67–84.
   Web of Science ®Google Scholar
• Bailey C, Bryla P, Malick A. (1996). The use of the intestinal epithelial cell culture model, Caco-2, in pharmaceutical development. Adv Drug Del Rev 22:85–103.
   Web of Science ®Google Scholar
• Bajerski L, Cardoso SG, Diefenbach IF, Malesuik MD, Sílvia H, Borgmann M. (2005). Liquid chromatographic determination of cetirizine in oral formulations. J AOAC Int 88:424–427.
   PubMed Web of Science ®Google Scholar
• Bakker RA, Timmerman H, Leurs R. (2002). Histamine receptors: Specific ligands, receptor biochemistry, and signal transduction. Clin Allergy Immunol 17:27–64.
   PubMedGoogle Scholar
• Chen C, Hanson E, Watson JW, Lee JS. (2003). P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists. Drug Metab Dispos 31:312–318.
   PubMed Web of Science ®Google Scholar
• Chen X, Zhang Y, Zhong D. (2004). Simultaneous determination of chlorpheniramine and pseudoephedrine in human plasma by liquid chromatography-tandem mass spectrometry. Biomed Chromatogr 18:248–253.
   PubMed Web of Science ®Google Scholar
• Crowe A. (2002). The influence of P-glycoprotein on morphine transport in Caco-2 cells. Comparison with paclitaxel. Eur J Pharmacol 440:7–16.
   PubMed Web of Science ®Google Scholar
• Crowe A, Diep S. (2008). pH dependent efflux of methamphetamine derivatives and their reversal through human Caco-2 cell monolayers. Eur J Pharmacol 592:7–12.
   PubMed Web of Science ®Google Scholar
• Crowe A, Lemaire M. (1998). In vitro and in situ absorption of SDZ-RAD using a human intestinal cell line (Caco-2) and a single pass perfusion model in rats: Comparison with rapamycin. Pharm Res 15:1666–1672.
   PubMed Web of Science ®Google Scholar
• Devillier P, Roche N, Faisy C. (2008). Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine: A comparative review. Clin Pharmacokinet 47:217–230.
   PubMed Web of Science ®Google Scholar
• Fromm MF. (2004). Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci 25:423–429.
   PubMed Web of Science ®Google Scholar
• Geha RS, Meltzer EO. (2001). Desloratadine: A new, nonsedating, oral antihistamine. J Allergy Clin Immunol 107:751–762.
   PubMed Web of Science ®Google Scholar
• Gillard M, Chatelain P. (2006). Changes in pH differently affect the binding properties of histamine H1 receptor antagonists. Eur J Pharmacol 530:205–214.
   PubMed Web of Science ®Google Scholar
• Haas H, Panula P. (2003). The role of histamine and the tuberomamillary nucleus in the nervous system. Nat Rev Neurosci 4:121–130.
   PubMed Web of Science ®Google Scholar
• He Y, Liu Y, Zeng S. (2010). Stereoselective and multiple carrier-mediated transport of cetirizine across Caco-2 cell monolayers with potential drug interaction. Chirality 22:684–692.
   PubMed Web of Science ®Google Scholar
• Hindmarch I, Johnson S, Meadows R, Kirkpatrick T, Shamsi Z. (2001). The acute and sub-chronic effects of levocetirizine, cetirizine, loratadine, promethazine and placebo on cognitive function, psychomotor performance, and weal and flare. Curr Med Res Opin 17:241–255.
   PubMed Web of Science ®Google Scholar
• Kan WM, Liu YT, Hsiao CL, Shieh CY, Kuo JH, Huang JD, Su SF. (2001). Effect of hydroxyzine on the transport of etoposide in rat small intestine. Anticancer Drugs 12:267–273.
   PubMed Web of Science ®Google Scholar
• McDonald K, Trick L, Boyle J. (2008). Sedation and antihistamines: An update. Review of inter-drug differences using proportional impairment ratios. Hum Psychopharmacol 23:555–570.
   PubMed Web of Science ®Google Scholar
• Molimard M, Diquet B, Benedetti MS. (2004). Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. Fundam Clin Pharmacol 18:399–411.
   PubMed Web of Science ®Google Scholar
• Obradovic T, Dobson GG, Shingaki T, Kungu T, Hidalgo IJ. (2007). Assessment of the first and second generation antihistamines brain penetration and role of P-glycoprotein. Pharm Res 24:318–327.
   PubMed Web of Science ®Google Scholar
• Petri N, Tannergren C, Rungstad D, Lennernäs H. (2004). Transport characteristics of fexofenadine in the Caco-2 cell model. Pharm Res 21:1398–1404.
   PubMed Web of Science ®Google Scholar
• Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS. (2001). Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther 299:620–628.
   PubMed Web of Science ®Google Scholar
• Polli JW, Baughman TM, Humphreys JE, Jordan KH, Mote AL, Salisbury JA, Tippin TK, Serabjit-Singh CJ. (2003). P-glycoprotein influences the brain concentrations of cetirizine (Zyrtec), a second-generation non-sedating antihistamine. J Pharm Sci 92:2082–2089.
   PubMed Web of Science ®Google Scholar
• Purohit A, Melac M, Pauli G, Frossard N. (2004). Comparative activity of cetirizine and desloratadine on histamine-induced wheal-and-flare responses during 24 hours. Ann Allergy Asthma Immunol 92:635–640.
   PubMed Web of Science ®Google Scholar
• Raeissi SD, Hidalgo IJ, Segura-Aguilar J, Artursson P. (1999). Interplay between CYP3A-mediated metabolism and polarized efflux of terfenadine and its metabolites in intestinal epithelial Caco-2 (TC7) cell monolayers. Pharm Res 16:625–632.
   PubMed Web of Science ®Google Scholar
• Ruperez FJ, Fernandez H, Barbas C. (2002). LC determination of loratadine and related impurities. J Pharmaceut Biomed Anal 29:35–41.
   PubMed Web of Science ®Google Scholar
• Russell T, Stoltz M, Weir S. (1998). Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers. Clin Pharmacol Ther 64:612–621.
   PubMed Web of Science ®Google Scholar
• Scavone JM, Luna BG, Harmatz JS, von Moltke L, Greenblatt DJ. (1990). Diphenhydramine kinetics following intravenous, oral, and sublingual dimenhydrinate administration. Biopharm Drug Dispos 11:185–189.
   PubMed Web of Science ®Google Scholar
• Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CA, van der Valk MA, Robanus-Maandag EC, te Riele HP. (1994). Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491–502.
   PubMed Web of Science ®Google Scholar
• Seelig A, Landwojtowicz E. (2000). Structure-activity relationship of P-glycoprotein substrates and modifiers. Eur J Pharm Sci 12:31–40.
   PubMed Web of Science ®Google Scholar
• Shirasaka Y, Kawasaki M, Sakane T, Omatsu H, Moriya Y, Nakamura T, Sakaeda T, Okumura K, Langguth P, Yamashita S. (2006). Induction of human P-glycoprotein in Caco-2 cells: Development of a highly sensitive assay system for P-glycoprotein-mediated drug transport. Drug Metab Pharmacokinet 21:414–423.
   PubMed Web of Science ®Google Scholar
• Simons FE. (2004). Advances in H1-antihistamines. N Engl J Med 351:2203–2217.
   PubMed Web of Science ®Google Scholar
• Snowman AM, Snyder SH. (1990). Cetirizine: Actions on neurotransmitter receptors. J Allergy Clin Immunol 86:1025–1028.
   PubMed Web of Science ®Google Scholar
• Tavares V, Macedo CC, Montanhez L, Barros FA, Meurer EC, Campos DR, Coelho EC, Calaffati SA, Pedrazzoli J Jr. (2007). Determination of dimenhydrinate in human plasma by liquid chromatography-electrospray tandem mass spectrometry: application to a relative bioavailability study. J Chromatogr B Analyt Technol Biomed Life Sci 853:127–132.
   PubMed Web of Science ®Google Scholar
• Troutman MD, Thakker DR. (2003). Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res 20:1210–1224.
   PubMed Web of Science ®Google Scholar
• Tsuji A, Tamai I. (1996). Carrier-mediated intestinal transport of drugs. Pharm Res 13:963–977.
   PubMed Web of Science ®Google Scholar
• Uchida Y, Ohtsuki S, Kamiie J, Terasaki T. (2011). Blood-brain barrier (BBB) pharmacoproteomics: Reconstruction of in vivo brain distribution of 11 P-glycoprotein substrates based on the BBB transporter protein concentration, in vitro intrinsic transport activity, and unbound fraction in plasma and brain in mice. J Pharmacol Exp Ther 339:579–588.
   PubMed Web of Science ®Google Scholar
• Uno T, Yasui-Furukori N, Takahata T, Sugawara K, Tateishi T. (2004). Liquid chromatographic determination of fexofenadine in human plasma with fluorescence detection. J Pharm Biomed Anal 35:937–942.
   PubMed Web of Science ®Google Scholar
• Walsh GM, Annunziato L, Frossard N, Knol K, Levander S, Nicolas JM, Taglialatela M, Tharp MD, Tillement JP, Timmerman H. (2001). New insights into the second generation antihistamines. Drugs 61:207–236.
   PubMed Web of Science ®Google Scholar
• Wang EJ, Casciano CN, Clement RP, Johnson WW. (2001). Evaluation of the interaction of loratadine and desloratadine with P-glycoprotein. Drug Metab Dispos 29:1080–1083.
   PubMed Web of Science ®Google Scholar
• Webb CL, Eldon MA. (1991). Sensitive high-performance liquid chromatographic (HPLC) determination of diphenhydramine in plasma using fluorescence detection. Pharm Res 8:1448–1451.
   PubMed Web of Science ®Google Scholar